Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke
Study Details
Study Description
Brief Summary
This is a prospective cohort study to investigate the early impact of evolocumab on patients with acute ischemic stroke (AIS) in China. Evolocumab, a proprotein convertase subtilisin/kexin taye 9 inhibitor, can significantly reduce low density lipoprotein cholesterol (LDL-C) levels and has a positive effect on improving cardiovascular events. However, existing studies have focused almost exclusively on the long-term effects of Evolocumab, and the early effects of Evolocumab on AIS patients remains unclear.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Detailed Description
Patients aged 18-80 years old admitted to the Department of Neurology, Xuanwu Hospital, Capital Medical University, with a definite diagnosis of acute ischemic stroke and receiving lipid-lowering therapy with statins with or without evolocumab will be included in this study. Participants will be divided into two groups according to the lipid-lowering therapy they used: 1) statin-alone group: the participants receive statins alone (atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn) for lipid reduction, and 2) PCSK9-i group: the participants receive statins (atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn) and evolocumab (140mg twice a month) for lipid reduction. Most importantly, the lipid-lowering therapy of participants will be decided only by clinicians not involved in the study, not by the investigators. The levels of blood lipid (TC, TG, HDL-C, LDL-C, Apo AI and Apo B) and inflammatory biomarkers (hsCRP and IL-6) of these participants at different time points (day 1, day 3, day 5, and month 3) will be recorded. The target level of LDL-C is the LDL-C reduction ≥50% from the baseline and LDL-C<1.4mmol/L (55mg/dL). In addition, the cardiovascular events and adverse drug reactions of these participants during follow-up will also be recorded. During the follow-up period (3 months), participants who changed their lipid-lowering regimen, including the type, dosage and frequency of statins and evolocumab, will be excluded from the study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Statin-alone group The participants in statin-alone group receive statins alone for lipid reduction. |
Drug: Statins
Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
Other Names:
|
PCSK9-i group The participants in PCSK9-i group receive statins and evolocumab for lipid reduction. |
Drug: Statins
Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
Other Names:
Drug: Evolocumab
Evolocumab 140mg twice a month, subcutaneous injection
Other Names:
|
Outcome Measures
Primary Outcome Measures
- LDL-C target achievement rate on Day 5, Month 3 [Day 5, Month 3]
LDL-C target achievement rate= Number of patients who achieved the LDL-C target level/ Total number of follow-up patients
Secondary Outcome Measures
- Percentage change in LDL-C level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in LDL-C level= (follow-up LDL-C level - baseline LDL-C level)/ baseline LDL-C level
- Percentage change in HDL-C level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in HDL-C level= (follow-up HDL-C level - baseline HDL-C level)/ baseline HDL-C level
- Percentage change in TC level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in TC level= (follow-up TC level - baseline TC level)/ baseline TC level
- Percentage change in TG level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in TG level= (follow-up TG level - baseline TG level)/ baseline TG level
- Percentage change in Apo AI level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in Apo AI level= (follow-up Apo AI level - baseline Apo AI level)/ baseline Apo AI level
- Percentage change in Apo B level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in Apo B level= (follow-up Apo B level - baseline Apo B level)/ baseline Apo B level
- Percentage change in hsCRP level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in hsCRP level= (follow-up hsCRP level - baseline hsCRP level)/ baseline hsCRP level
- Percentage change in IL-6 level on Day 1, Day 3, Day 5, and Month 3 [Day 1, Day 3, Day 5, Month 3]
Percentage change in IL-6 level= (follow-up IL-6 level - baseline IL-6 level)/ baseline IL-6 level
- Percentage of mRS≤2 on Month 3 [Month 3]
Percentage of mRS≤2= Number of patients with mRS≤2/ Total number of follow-up patients
- Incidence of major cardiovascular events on Month 3 [Month 3]
Major cardiovascular events: stroke, cardiovascular death, myocardial infarction, hospitalization for unstable angina, and coronary revascularization.
- Incidence of adverse events on Month 3 [Month 3]
Adverse events: injection site reaction, anaphylaxis, myopathy, abnormal liver function, new onset diabetes, cognitive impairment, and hemorrhagic cerebral infarction.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with acute ischemic stroke;
-
Aged 18-80 years, gender unlimited;
-
The fasting LDL-C≥1.8mmol/L (70mg/dL);
-
Received lipid-lowering therapy with statins with or without evolocumab;
-
Premorbid mRS ≤ 2;
-
NIHSS ≤ 15;
-
Subjects participated in the study voluntarily and signed informed consent.
Exclusion Criteria:
-
Participants who changed their lipid-lowering regimen;
-
Participants allergic to PCSK9 inhibitors;
-
Participants treated with cholesterol ester transfer protein inhibitor within 12 months prior to enrollment;
-
LDL or plasma apheresis within 12 months prior to enrollment;
-
Last known left ventricular ejection fraction < 30%
-
Known hemorrhagic stroke at any time;
-
Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 at final screening;
-
Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times;
-
Pregnant or lactating women;
-
Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 3 years.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Xuanwu Hospital, Beijing
Investigators
- Study Chair: Meng Ran, PhD, Xuanwu Hospital, Beijing
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RMeng